482 results on '"Vestbo, Jorgen"'
Search Results
2. The fibroblast hormone Endotrophin is a biomarker of mortality in chronic diseases
3. Lung-function trajectories: relevance and implementation in clinical practice
4. Predicting exacerbations in COPD in the Danish general population
5. Impact of the metabolic syndrome on cardiopulmonary morbidity and mortality in individuals with lung function impairment: a prospective cohort study of the Danish general population
6. Clinical trials of pneumonia management assess heterogeneous outcomes and measurement instruments
7. Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum
8. Plasma immunoglobulin E and risk of exacerbation and mortality in chronic obstructive pulmonary disease: A contemporary population-based cohort
9. Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study
10. The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study
11. Potential clinical implications of targeted spirometry for detection of COPD: A contemporary population-based cohort study
12. Exacerbation history, severity of dyspnoea and maintenance treatment predicts risk of future exacerbations in patients with COPD in the general population
13. Changes in lung function in European adults born between 1884 and 1996 and implications for the diagnosis of lung disease: a cross-sectional analysis of ten population-based studies
14. Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)
15. Mechanisms Underlying the Association of Chronic Obstructive Pulmonary Disease With Heart Failure
16. Asthma and COPD versus phenotypic traits: Toward precision medicine in chronic airway disease
17. Supernormal lung function and risk of COPD: A contemporary population-based cohort study
18. Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease: Which One(S), How, and When?
19. Machine Learning and Prediction of All-Cause Mortality in COPD
20. End-product of fibrinogen is elevated in emphysematous chronic obstructive pulmonary disease and is predictive of mortality in the ECLIPSE cohort
21. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial
22. Prognosis of COPD depends on severity of exacerbation history: A population-based analysis
23. Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial.
24. Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups
25. Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study
26. Left ventricular volume and wall stress are linked to lung function impairment in COPD
27. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease
28. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial
29. The revised GOLD 2017 COPD categorization in relation to comorbidities
30. COPD Assessment Test (CAT) Score according to the presence/absence of accelerated lung function decline in young adult smokers with normal FEV1
31. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial
32. The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort
33. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial
34. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics
35. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial
36. Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study
37. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary
38. Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD
39. A Sensitivity Analysis of Secular Trends in Risk Factors and Mortality Based on Cohort Studies
40. A Comparison of Mortality Rates in Three Prospective Studies from Copenhagen with Mortality Rates in the Central Part of the City, and the Entire Country
41. Gender and Smoking-Related Risk of Lung Cancer
42. Measuring spirometry in a lung cancer screening cohort highlights possible underdiagnosis and misdiagnosis of COPD
43. Rapid Detection of Cytomegalovirus in Bronchoalveolar Lavage Fluid and Serum Samples by Polymerase Chain Reaction: Correlation of Virus Isolation and Clinical Outcome for Patients with Human Immunodeficiency Virus Infection
44. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial
45. Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study
46. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial
47. Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis
48. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial
49. Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort
50. Medically treated exacerbations in COPD by GOLD 1-4: A valid, robust, and seemingly low-biased definition
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.